Historique
Article de Périodique
A controlled trial of buprenorphine treatment for opium dependence: the first experience from Iran (2002)
(Essai contrôlé de traitement de la dépendance aux opiacés par la buprénorphine : première expérience irannienne)
Auteur(s) :
AHMADI, J.
Année
2002
Page(s) :
111-114
Langue(s) :
Français
Refs biblio. :
18
Domaine :
Drogues illicites / Illicit drugs
Thésaurus mots-clés
OPIACES
;
BUPRENORPHINE
;
DEPENDANCE
;
TRAITEMENT DE MAINTENANCE
;
RETENTION
;
EVALUATION
Thésaurus géographique
IRAN
Note générale :
Drug and Alcohol Dependence, 2002, 66, (2), 111-114
Note de contenu :
tabl.
Résumé :
ENGLISH :
Aims: To evaluate the effect of a 4 mg/day sublingual dose of buprenorphine in the maintenance treatment of opium dependence in comparison with a 1 mg/day dose over an 18-week treatment period. As a secondary objective, the results were determined concurrently for subjects treated with a 2 mg/day dose. Design: Subjects were assigned randomly to three dosage groups. Participants: 330 consecutive (320 men and 10 women) opium addicts who met the DSM-IV criteria for opioid dependence and were seeking treatment. Intervention: Subjects received a 1, 2 or 4 mg/day dose of buprenorphine and were treated in an outpatient clinic where they also received a weekly 1-hour clinical counseling session. Measurements: Addiction Severity Index, retention in treatment, and illegal opioid use as determined by random urine testing. Findings: The mean age was 37.5 years (SD = 11.4, range 19-72). Overall, 194 (58.8%) of the patients completed the 18 week study. Completion rates by dosage groups were 47.3% for the 1 mg group, 58.2% for the 2 mg group and 70.9% for the 4 mg group (X2 = 12,7, df = 2, P = 0.0017). Conclusions: The results support the efficacy and safety of buprenorphine for opium addiction and suggest that an adequate dose of buprenorphine would help to increase the success rate. (Author's abstract.)
Affiliation :
Dept. Psychiatr., Shiraz Univ. Med. Sci., PO Box 71345-1416, Shiraz
Iran. Iran.
Iran. Iran.
Cote :
Abonnement